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-~~ -~~1J~I.! llltUG AliSORPTIOt>; l'HllHL!;S UTILILH;G ntL UES/ir.,\ RCSOi·lAT 
,\bstract of Uissertation 
An in vitro method t•;:;s tcstet! whereby the processes of dissolution .~nd dis-
trilJutimlof-,u::tivc ingredient into a lipoid solvent t.·ere con1liined in ur.e model 
and evaluated. 
The objectives of this research project t•crc: (1) to evaluate the efficacy 
of the in vitro r:!oJcl tnown as tile De saga Resomat, in the testing of .(!;astro-
intco;titliiY-:·:iL;""sO-rptlOn; {2) to apply the proccliurc ::m.J instnu~cnt to a grcup of 
therapeutically important products in detcrminig their absorption charactcristicsi 
(3) to !!raphically iJ lust rate the absorption profile of a specific drug as per 
cent ab5orbcd vs. time, simulating in _vivo absorption: (·I) to .compare the profile 
data ~itn cxpeirmentnllf dctcrmineJlfiSSoTution studies; (5) to relate, biotlhama-
ccutically the application of the profile data to absorption characteristics. 
A literature survey was perfunned including the history of dissolution rate 
mcthotl.:llogy and its influ('ncc on the bio.:lvailahility of medication from the dosage 
form. · 
A discussion of tile exyci'intental procedure h·as presented including the grapiti, 
cal illustration of tile resorption profiles for the three commonly known drugs 
used in the verification of tile apparatus. 
The rr.cthod \Oi"::IS applied to a group of therapeutically im!l<Jrtant products, 
spccificall}, thia::idc diuretics as t;ell as non-thiazide diUl"<:.lics such as 
Spironolactone, 1\cetazolanlidc, lthi:tcrynic Acid, Chlorthalil.!')r.t", <1nri Furosemide, 
Uissolution properties for each drug I>."Cre determined us.i,ng the !Jesaga 
as wei J as the '"Beaker i•lcthod1 of Levy and l!aye~, The mctl~tJ~ :..•$cU. ln this ~o:..-.rk 
involved the usc of a glass mpdcl apparatus t<~·hich 5huw~J t!t~ ba.lii~ }llly~ical· and 
chemical principleS of t)ic absorptio11 proces:::, nrn:1ely, th~ s<:>I~11!i._iitt Qf n !.irus; 
in the at1ucous ph\lSC a11d iu ~ht:rib~t.ion into q Epc.i!.l i'no,9, li!O. !)asagiJ fYJM 
was l'htccd into ati aqw;~ou:s buffered !iolut1Qn. ·rhc lllf of' the: l•01i.i'er~J al1luticn 
wns adjusted so as to corrCSJICOnJ to the t'll of the: gast:ro~c.mtera1 syt'item. M a. 
result of pressure chau~es corrcsjlDndiug to JlCristalsi.5 the ~lS$olvcll drut:; &'l.i.S$Cd 
througll a sinter and was them :~ubJccted to distributlor, with 1.1 suitable lipoid 
solvent. Th~ allsorption Jlrofilu wcro detcnnined by measuring, Sl'cctrophotc;m~trj­
Call>'. the concentration of the drug in the lipoid phase. Grn.phical displars 
constructed representing the solubility and distribution of the Lirug at spC!:ific 
pll-timc-intervals. 
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'INTRODUCTION 
The dissolution rate of a drug has a marked effect 
upon its absorption from a solid dosage form. This fact has 
led to an increasing interest in.developing in vitro dissolu-- . 
tion rate tests that can be compared with !a ~ absorption 
rate studies for possible use in quality control or for 
establishing official standards. 
Many investigators are concerned with the mechanisms 
and requirements for the absorption of new drugs. Pharma-
cologists are using the many means at their disposal in 
attempting to regulate the amount and rate of gastro-enteral 
absorption. Analysts are confronted with the problem of 
checking the availability of drugs in such preparations, with 
acceptable accuracy. It is true that in the final analysis, 
determinations of blood levels and elimination studies on 
animals or humans provide the most valid answers to many of 
jthe questions on absorption. However, these studies are 
associated with a number of disadvantages: in vivo tests are --
very time consuming and are, therefore, expensive: because of 
i 
'individual differences, they often have very poor reproduci-
bility which necessitates statements of universal validity 
only from a relatively large number of experimental subjects; 
finally, the results of a blood level analysis are always of · 






and elimination (1). 
Because of these disadvantages, efforts have been · 
made for several years to learn and master the factors influ-
encing drug absorption. Physical-chemical determinations such 
as dissolution rate and partitioning studies could provide a 
more specific picture than ~ ~ experiments. 
The over-all absorption process for solid drugs con-
sists of the dissolution step followed by drug partitioning 
into an essentially lipid barrier. This process of absorp-
tion is generally studied ~ vitro as two separate processes, 
each of which might be rate limiting. 
It has been shown in ·recent years tha.t the rate of 
disintegration of a tablet does not provide useful informa-
tion on the absorption of the drug (1). Currently, ~vitro 
tests do not consider this absorption factor. Consequently, 
an ~ vitro test apparatus was developed in which absorption 
model experiments on the basis of dissolution and lipid dis-
tribution can be determined. 
A glass model apparatus has been developed by Dibbern 
(1) which simulates the human digestive tract, whereby the 
processes of dissolution and distribution coefficients of 
drugs are represented and evaluated, combined in one model. 
The glass model apparatus has been called the Desaga Resomat.a 
The Desaga Resomat makes it possible to determine the 
amount of drug, which has been dissolved in. simulated 
a - Available from Brinkmann Instruments, Co., Westbury, N. Y. 
3 
digestive juices and that has been transferred into a lipoid 
phase as a result of distribution. The absorption res1..1lts 
are obtained from two factors which control !!l.~.absorp­
tion, 'namely, aqueous solubility and distribution character-
istics. These distribution characteristics are currently 
referred to as the partition coefficients of the drug. 
The drug, either as a pure substance or in an oral 
dosage form, is subjected to a buffered solution correspond-
ing to digestive juice. This solution is contained in the 
inner cylinder of the Resomat. Alternating pressure changes 
within the model produced an effect corresponding to peri-
stalsis. As a result, the dissolved drug passes through an 
asbestos filter where it is subjected to distribution with 
a suitable lipoid solvent contained in the outer vessel. 
The drug concentration of the lipoid phase can be 
determined at definite time intervals or continuously by 
using the peristaltic pump, a component part of the apparatus. 
Thus, by using this principle of distribution, the course of 
\ gastro-enteral absorption can be followed by changing the pH 
'of the aqueous phase stepwise to correspond with that of 
hysiological pH. The distribution process would operate 
continuously throughout these pH changes. A characteristic 
'absorption profile for the drug under test would then be 
~lotted. Another application ~f the Desage Resomat is the 
tetermination of the simple solubility rate of a pure drug 
rr its rate of release from the oral dosage form without con-
"ideration of the distribution behavior. 
II 
Consequently, this unique apparatus coul.d.be used.to 
study any therapeutic group of .drugs for e\hiluating their 
solubilities and .distribution characteristics. The .derived 







SURVEY OF THE LITERATURE 
In 1966, Dibbern (1, 2) reported that the factors 
lying bett'leen the oral administration and it.s measurable 
pharmacological or clinical effects are very complicated •. 
In the past, it was considered satisfactory to take the 
drug action as the summation of all these factors. However, 
during the last few years, attempts have been made to-dif-
ferentiate and study individually the sequence of events 
involved in drug absorption. These events include gastro-
enteral. resorption, drug transport, protein binding, plasma 
levels, metabolism, excretion, and receptor site mechanisms. 
The increasing knowledge of the individual mechanisms 
can be taken into consideration in the synthesis of new com-
pounds and the formulation of therapeutically effective 
]dosage forms. The separate studies of the individual pro-
'lcesses could be rendered possible with the help of test 
models. Therefore, these models would differ from the com-
plexities of !n ~ evaluations by expressing basic princi-
ples in a manner easier to understand and visualize. 
Shore a:nd his co-workers (3, 4) showed the importance 
rf the distribution between an aqueous and lipoid phase in 
jthe determination of the absorption of organic drugs. They 
remonstrate that compounds with basic or acidic functions 
~e absorbed only in their nonionized state, lipoid soluble 




" . I' 
soluh.ili ty, the greater the gast.ro-enteral absorption. 
'l'he dis sol uti on of the drug in the digestive juices 
can be ass~med to represent the first condition for gastra-
l, enteral resorption. A sufficiently high distribution 
6 
coefficient \vould represent the second condition. Depending 
on the ionic characteristics of the drug, one or the other of 
the aforementioned conditions can be the limiting factor for 
the resorption quota. Resorption resulting from aqueous 
dissolution and then lipoid distribution represents a har-
monious physiological process. The rate at which the drug 
can penetrate the lipoid barrier of the mucosa is based upon 
the degree of partitioning into the lipoid solvent which in 
turn is controlled by ·the aqueou.s characteristics of the 
drug and the pH of the solution. This pH variable controls 
]the degree of nonionized state of the drug, which is the form 
necessary for the partitioning process. Accordingly, as the 
pH dependent nonionized form of the diug dissolved in the 
lipoid phase, more becomes available from the aqueous dissolu-
tion process with subsequent ionic conversion. 
There have been several reports on the mechanics for 
[the determination of dissolution rates, but they do not 
'fns~Ter satisfactorily all of the questions about "resorption" 
jin the form they are described. It was for this reason that 
!loth "resorption" conditions, i.e., water solubility and 
ristribution coefficient, be represented and combined into 
,the model. 
1\.s indicated formerly (1) 1 there was adequate evidence 
7 
. to conclude that the rate at which a drug diss·olves from its 
intact or fragmented dosage forms in the humangastro-
intestinal tract often controlled the rate at which the drug 
appears in the blood. It was also shown that in many cases 
in vitro dissolution results could be used to explain observed 
differences in in ~ determinations. It should be noted, 
however, that the rates of the processes of disintegration 
and dissolution were both dependent upon the composition and 
method of formulation of the dosage form. Therefore, con-
trolled pharmaceutical procedures could be used to alter the 
jrate of release from the. dosag~ form. 
kate of Dissolution - Historical Highlights 
\ :tn 1896, Noyes and Whitney (6) published a statement 
of their .law which concerns the rate at t-thich solids dissolve 
1 
tn their own solutions. The law resulted from experiments in 
I 
'which they measured the amount of a substance dissolved at 
~iifferent time intervals when constant surface cylindrical 
rticks of the substance were rotated in water. They explained 
·~e dissolution process on the assumption that a very thin 
layer of saturated solution was formed at the surface of the 
I . 
folid. The rate at which the solid dissolved was governed 
I . 
ry the rate of diffusion from this saturated layer into the 
,lain body of the solution. 
Nernst and Brunner ( 7) advanced the Noyes-~1hi tney Law 
o include all kinds of heterogeneous reactions. They used 
ick's Law of Diffusion to establish a relationship between 
fue proportionality constant involved and the diffusion 
8 
coefficient of the solute. ·In this way, they "lEite able to 
estimate the thickness of the diffusion layer a:tthe surface 
of the solid. 
In 1931, Hixson and Crowell (8) introduced their 
"cube root" ~aw based upon the rate of solution of a solid 
in a liquid as a function of agitation. The "cube root" law 
was used to analyze the factors .involved in the process of 
agitation. 
Cofman (9) was the first investigator to determine 
the rate of dissolution of a compressed tablet by designing 
an apparatus known as the "sol~ometer." It was based on the 
increase of buoyancy of the apparatus in water as the tablet 
went into solution. 
Elliott (10) illustrated graphs showing the amount of 
drug dissolved versus time, using the apparatus developed 
by Cofman. He showed the influence of the temperature of 
the dissolution medium and the surface area of the dosage 
form upon the rate of dissolution~ 
Oser (11~ in 1945, employed urinary excretion .data in 
proposing the concept of physiological availability of the 
vitamins from pharmaceutical dosage forms. Results showed 
that a direct relationship existed in normal subjects between 
the urinary excretion of water-soluble vitamins and the amount 
ingested. 
Nelson (12) explained the differences in blood levels 
of theophylline salts and the prolongation of these levels 
Of theophylline salts after oral administration by showing 
., ·. 
9 
the differences in the in viti,§ i'ata~ of dissolution of these 
salts. 
Higuchi (13), in 1958, studied the influence of bases 
and buffers on the dissolution rates of acidic solids. He 
used the dissolution constants of the acids and bases involved 
in the study to derive a simple equation to mathematically 
express the dissolution rate phenomenon• 
Royal (14) compared the ~ vitro rate of release of 
various formulations of dextroamphetamine sulfate sustained 
release capsules by using a modified u.s.P. tablet disinte-
gration apparatus. He found that the ~ vitro rate of release 
varied with each capsule formulation. He also noted that the 
rate of release varied with changes in agitation making corre-
lation of results with other methods difficult. 
Wiegand (15) introduced a mathematical expression 
which described ~ vitro release curves of several sustained 
release dosage forms. His equation was useful in correlating 
release of active ingredient from the dosage form with physio-
logical availability. 
At the same time, Wagner (16) derived an equation 
which allowed the calculation of the instantaneous rate of 
release of active ingredient at any·given time during the 
~vitro test. 
Nelson (17) reviewed and discussed the theoretical 
basis for application of urinary excretion data to evaluation 
of drug absorption. He applied the concept of excretion data 
to show how .:!:!l vivo solution. rate, limits the absorption of 
: i-: 




aspiri.nand benzyl penicillin after drril administration~ 
Nash and Marcus (18), in 196'0, described another. 
apparatus and method for the ~ vitic evaluation of sustained 
release products. The advantage of simplicity, convenience, 
and versatility were illustrated, as well as the variables 
which affected the ~vitro test procedure • 
. In the same year, Campbell (19) evaluated sustained 
action release rates of various dosage forms. He pointed 
out that sustained release properties apparently were not 
being evaluated properly by the methods presently in use, 
since physiological availabili"\:y could not be predicted 
accurately from ~ vitro and ~ ~ tests in use. It was 
suggested that all claims for sustained release be based on 
adequately controlled ~vivo tests; quantitatively related 
to dose, until more information regarding i!!, vitro tests 
\becomes available. 
1
', . J:n 1960, Levy and Hayes (20) described a dissolution 
assembly referred to as the "beaker" method which provided 
I 
]information on the physico-chemical aspects on the buffered 
1acetylsalicylic acid controversy. 
Also in 1960, i'lagner and co-workers (21) presented 
1,rork which involved the comparison of plasma levels of pred-
risolone in man after oral administration of two types of 
! 
~anules containing the active ingredient. The dissolution 
tf one type was dependent on the pH while the other was not. 
~. t the sam~ time, they attempted to correlate these results 





' 1.-i~: ' 
t . 
11 
results between the two .types Cif granules, the rates of 
release differed. However, when comparing the .!D. ~ results 
derived from both types of granules, they were not able to 
demonstrate significant differences in plasma levels. 
Levy (22) in another study determined the absorption 
rates of several types of commercial aspirin tablets by a 
urinary excretion method. His results showed that the ~ vivo 
absorption rate was proportional to the ~ vitro dissolution 
rate. He proposed at this time that the u.s.P. tablet dis-
integration test be replaced by a dissolution test. 
In 1963., l~agner (23) established biopharmaceutics as 
an important parameter in testing pharmaceutical formulations, 
stressing the significance of dissolution rate studies. 
Hamlin and co-workers (24) determined the ~ vitro 
dissolution rates of two different polymorphic forms of 
methylprednisolone. They shol-red that increased agitation of 
the dissolution apparatus prevented them from distinguishing 
any difference in the dissolution rates of the two polymorphs. 
They emphasized the need for controlled intensities of agita-
tion during in vitro dissolution tests. 
Schroeter and co-workers (25) reported that a quantita-
tive relationship existed between r~te of dissolution and 
disintegration time in certain tablet formulations. They 
correlated physiological availability ofp-aminosalicylate 
with not only dissolution rate but also with disintegration 
time. Also the~r results questioned the validity of the 















Schroeter and Wagner (26), iti 1962, described the 
first automated dissolution rate apparatus. They employed 
the use of a timer-controlled sampling system which auto-· 
12 
matically removed filtered samples from the dissolution rate 
apparatus and recorded the absorption of the sample as a 
function of time. The method was later modified by Schroeter · 
1 and Hamlin (27) by using a one rnm. flow cell which prevented 
\ collection of insoluble tablet additives in the cell. Further 
1 modification of the system prevented diminution of flow rate 
I due to a clogged filter. This was accomplished by shunting 
\the circulation stream away fr~m the filter except during 
\
actual recording of the dissolution process. 
Niebergall and Goyan (28) developed another automatic 
\
recording apparatus to follow the process of dissolution. 
\
Results were recorded as percent transmittance versus time • 
. Higuchi and Hiestand (29) derived an equation to 
·:iescribe the dissolution rate of a particle as a function 
j 
1)f time in their diffusion controlled dissolution process. 
I 
l-bey found that variation in particle size did affect the 
l!1" s. solution rate. Later, Higuchi and co-workers (30) applied 
\he equation to the dissolution rate of micronized methyl-
fednisolone in aqueous solutions and a correlation was 
ftained between experimental results and theory. 
l Levy and Tanski (31) described a rotating disk method 
rr the determination of dissolution rates. This method 
'!lowed for constant controlled speeds over extended periods 
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13 
Stelmach and co-workers (32) studied tM mechanism 
of release of a drug from its dosage form !.n vi!tro. They· 
stated that this information was ·necessary to in'cerpret absorp-
tion, distribution, and excretion data to predict physiological 
availability in vivo. --
Paikoff and Drumm (33) described a simple device which 
is useful for dissolution rate determinations of capsule 
formulations. The method allowed a visual inspection of the 
capsule dissolution. They used the procedure in the usual 
chemical dissolution rate determination for predicting possi-
ble problems of drug availability from capsules. 
Levy and co-workers (34) described a single ~ vitro 
dissolution rate test for a drug which correlated qtiantita-
tively with the gastro-intestinal absorption rate in man. 
They expected the !n vitro conditions .that yielded such 
correlations to be relatively.similar to dissolution condi-
1tions found ~ ~· They suggested that additional variables 
that affect availability in man be included in future ~ vitro 
tests to correlate in a more significant manner those in vitro -
•results with i:l!, ~ act.uality. They indicated that this 
]
1
could lead to a relatively generalized test procedure, suit--
Jable for product development and control purposes which could 
re ~ncl~d~d in official compendia as a test for physiologic 
·aval.labl.ll.ty. . · 
1 . Higuchi and co-workers (35, 36, 37,· 38) studied the 
'Importance of a number of factors controlling the rates of 










factors studied included the choicer crf. plastic, weight of 
drug incorporated in the matrix, seihlbility of the drug used, 
mat1·ix additives, and the role of solvent permeation ol: the 
matrix. They developed and applied theoretical models to 
illustrate their results. 
Knoechel and co-workers (39) studied the many vari-
ables in the tableting process using an instrumented rotary 
tablet machine. He also reported data on the relationship 
between rate of dissolution of the active ingredients with 
the compres.sional force on the tablet. 
The importance and usefulness of a polymorphic form 
l
of a drug to increase rate of dissolution can be measured by 
the work done by Higuchi and co-workers (40). They found 
fhat a correlation existed between the two polymorphic forms 
j 
'of sulfathiazole and methylprednisolone. They established 
1
1
that the meta-unstable polymorph had a greater rate of dis-
bolution which decreased as it reverted to the· more stable 
~~tate. 
1 
I Niebergall and co-workers (41) were the first to 
lnvestigate the simultaneous determination of the dissolution 
I . 
1: ::::.:::::::::·~.::::::·::::· .:·~:.:::::. 
re rate constant, which conformed to other methods reported. 
Jhe apparatus, however, did not allow for continuous rate 
\[terminations, or other significant variables. 
Finbolt and Solvang (42) studied the kinetics of in 
,.J;ro dissolution of phenacetin and phenobarbital in human 
,!S 
gastric juice, comparing it to hydrochloric acid dilutions 
containing various amounts of the surfactant, polysorbate 80. 
Ini::reased rate of dissolution in the presence 6£' the surfactant 
was shown to be due to a decrease in the inter£acial tension 
between the drug particles and the dissolution medium. The 
solubilizing properties of the surfactant were not significant. 
Castello and co-workers (43) described an apparatus in 
which twenty dissolution tests could be conducted simulta-
neously. Automatic and simultaneous sampling at predetermined 
time intervals was provided in the design of the apparatus. 
Pernarowski and co-workers (44) described an apparatus 
consisting of a closed dissolution container, a basket-stirrer 




pump to a flow cell in a sui table spectro-
I . Aguiar and co-w·orkers {45) evaluated the importance of 
iphysical and pharmaceutical factors involved in chlorampheni-
jpol release and availability from four commercial samples of 
bhloramphenicol. The study was carried out in three parts: 
I . 
·~a-aggregation determinations, dissolution studies, and 3:!! 
h tro qut permeation. A correlation between drug release as 
I 
reflected by the de-aggregation and dissolution rate and 
fhloramphenicol plasma levels in humans was demonstrated. 
Barzilay and Hersey (46) described an automated dialy-
is method :for measuring the dissolution profiles of tablet 
osage forms. The suitab.ility of the method for the evalua-
ion of these profiles has been demonstrated by an examination 
, I' 
' ' t· 
'i. :· 
of tablets of sulfathiazole prepared under ciii'ierent 
conditions of pressure and excipient con.te·hf.. 
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Tlngstad and Riegelrnan (47) descriBed a continuous 
flow apparatus for determination of rates of dissolution. 
This test produces a plot of instantaneous rate of dissolu-
tion versus time rather than the usual cumula·tive plot of 
percent dissolved versus time. 
Blythe (48) discussed a systematic approach to bio-
availability testing. He pointed out that in future years 
a great deal of effort will have to be expended to obtain 
the human and. the !a vitro data necessary to solve the generic 
equivalency problem. 
Langenbucher (49) described a new method for the assess-
ment of the dissolution behavior of solid dosage forms. The 
method, which is based upon the mass transfer between solid 
and liquid phase in an exchange column, is shown to avoid 
some disadvantages of the commonly used beaker methods employ-
ing fixed liquid volumes. Because of its reproducibility, 
the method seems useful for a meaningful study of dissolution 
kinetics. 
Fites and co-workers (50) studied the drug-permeability 
properties of several water insoluble films with respect to 
their potential application for the control of drug release 
from solid pharmaceutical dosage forms. Films composed of 
polyrnethylvinyl ether-maleic anhydride co-polymer, cross-
linked with polysorbate 20 appeared promising for the appli-
cation of film controlled drug-release applications. The' 
17 
permeability of the films can be controllecl by the appropriate . 
adjustment of their polysorbate 20 contF.Hit:; molecular weight 
of the polymer, and humidity pretreatment. 
Over the years, many papers have been introduced dis-
cussing the importance of dissolution rates and the variable 
factors that affect it. Wagner (51) pointed out that there 
appeared to be as many different types of dissolution rate 
apparatus and variations of established methods as there are 
investigators studying dissolution problems. However, as 
previously mentioned, an apparatus has been developed that 
very closely simulates the gastro-enteral tract.. It allows 
variability in agitation and in pH changes as it follows the 
simulated gastro-enteral course. This model test has been 
sho\m to compare with !!!. ~ tests. The graphical display 
of the resorption quota at predetermined pH-time-intervals, 
res~lts in characteristic curves for the individual drugs 
tested. Because of these factors, it was felt that by the 
use of this !!!. vitro test, it could be considered a valuable 
adjunct in predicting the absorption of drugs ~ ~· 
Wagner (51) also pointed out that future research, on 
dissolution rate studies should be directed towards establish-
ing scientifically realistic test apparatus for the purpose 
of predicting physiological availability from dosage forms. 
Accordingly, it was deemed feasible to apply the principles 
of the Desaga Resomat to investigate more thoroughly the dis-
solution study phenomenon. Thus, the objectives of this 

















1) to establish the efficacy of the Desaga Resomat 
as an instrument for the 1:E_ vitro testing of 
gastro-enteral·absorption. 
2) to apply this procedure and instrument to a 
group of therapeutically important products in 
determining their absorption characteristics. 
Specifically, this group will include the 
thiazide diuretics as well as non-thiazide 
18 
diuretics such as acetazolamide, spironolactone, 
ethacrynic acid, chlorthalidone, and furosemide. 
3) to graphically illustrate the absorption profile 
of a specific drug as percent absorbed versus 
time, simulating in ~ absorpt~on. 
4) to compare the profile data with experimentally 
determined dissolution studies by the "beaker 
method." 
5) to relate biopharmaceutically, the application 




ycrification of the Experimental Procedure 
Since the Desaga Resomat is a relatively new research 
instrument, it was necessary to verify the physical charac-
teristics of such a model. This apparatus, designed by 
Dibbern (1, 2) was employed throughout the course of this 
study. 
When there is a system consisting of dissolved and 
undissolved substances in an aqueous medium, the dissolved 
por.tion.of the substance would be available for distribution 
into an immiscible non polar phase. Distribution implies the 
partitioning of the dissolved substance from the aqueous laye~ 
across the interphase into the lipoid solvent. The extent of 
this partitioning will be based on the solvent characteristics 
of the substance in each of the respective solvents. · To 
accomplish this, it will be necessary for the dissolved sub-
stance to diffuse from the aqueous layer into the lipoid 
phase. 
The drugs employed to confirm the operation of the 
instrument were those selected by Dibbern (1, 2) in his origi-
nal study. He selected 50 mg. of each of the following for 
his test samples: acetylsalicylic acid, phenacetin, and 
phenobarbital. 
The apparatus, as illustrated in Figure 1 was set up 








SCHEMATIC DRAWING OF THE DESAGA RESO.MAT 
'I'' !) · .. 
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and the pressure equalizing "faucet" {C) was opened. A 
magnetic stirrer (D) of 40 mm. length tias inserted into the 
outer glass cylinder (E). Two-hundl:·ed lltls. of chloroform 
were then introduced into this cylinder. The inner glass 
cylinder (F~ containing a magnetic stirrer (G) of 30 mm. 
length, was lowered into the outer vessel so that the lot~er 
edge.of the inner vessel was immersed 2. ems. into the chloro-
form. Precautions were taken to prevent the asbestos fil-
ter (H) from coming in contact with the chloroform layer. 
While holding the inner vessel in this position, 100 mls. of 
simulated gastric fluid were slowly poured into.the inner 
glass cylinder through the opening (I). The simulated gastric 
fluid flowed dropwise through the asbestos filter onto the 
chloroform surface but remained within the inner cylinder. 
The inner glass cylinder was carefully guided onto the teflon 
coated standard taper joints and secured with a gentle twist. 
The air which remained between the filter and the aqueous 
phase above the chloroform was removed through the filter by 
sealing the tapered openings (K) and (L} and by applying a 
gentle vacuum at connection (J}. After equalizing the pres-
' sure within the closed apparatus, the space below the filter 
now consisted of a two phase system.of equal parts of simu-
lated gastric fluid and chloroform. 
The assembled glass apparatus was now placed upon the 
' 
mecha~lical module (M}. The 50 mg. samples of the drug under · 
test, were plac~d into the tablet basket (N), Which immersed 





placed into its appropriate setting. 1~~, opening (J) was 
then connected to the pump (O), locate:! in the module, with 
rubber tubing and the joints (K) and {Ll were sealed by the 
introduction of a combination glass electrodea (P) and a 
ground glass stopper respectively. 
The control knob (Q) located on the mechanical module 
was turned to the position marked "piston pump." With the 
pressure equalizing "faucet" open, the piston pump and the 
magnetic stirrer were turned on by depressing switches (R) 
and (S). The revol~tions per minute of the magnetic stirrer 
1 
were adjusted so that a vortex of about 15 mm. in diameter 
\was formed at the two phase boun~ary between the water and 
\lipoid solvent. 
\ The control knob (Q) was turned to "single removal," 
1 
to remove a chloroform sample containing the partitioning 
\
drug., '!'his was accomplished by closing the pressure equaliz-
ing "faucet" and turning the removal pump control knob (T} in 
I 
1\a counter-clockwise direction. This delivered a 5-ml. volume 
,Df the sample directly to a cuvetteb. Samples were taken at 
~ixty minute intervals and measured spectrophotometricallyc 
~t the appropriate wavelength. The sample was then returned 
I 
~-------
- Semi-Micro AG/AgCl internals, available from Corning 
Scientific Instruments, Medfield, Ma. 
- Spectrosil Cells, 10 mm. light path, available from Coleman 
Instruments Division, Maywood, Ill. 
- Hitachi-Perkin Elmer Model 139 Spectrophotometer, available 
from Perkin-Elmer, Norwalk, Conn. 
1: 
'' '" 
to the system through the "faucet" (AY bY, rotating the 
"removal pump" control knob (T) in a c:l.Ockwise direction 
thus imparting a vacuum to the system which removed the 
sample from the cuvette. This dissolution and resorption 
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distribution process was then continued by turning the con-
trol knob (Q) back to the position marked "piston pump" and 
by opening the pressureequalizing "faucet" (C). 
The alternating positive and negative pressure imposed 
on the system by means of the small piston pump simulated the 
natural peristaltic effect t~hich enabled the drug to pass 
through the filter. The aqueous layer was then in hydro-
static equilibrium with the chloroform laye1;. 
Standard curves that would relate absorbance to drug 
concentration were prepared in concentrations indicated in 
Table l and illustrated in Figures 2 to 4. After one hour 
durin9 which a sample had been removed, tested, and returned 
to the apparatus, the simulated gastric fluid at an initial 
pH of 1.2 was brought to the pH 4.0 by the addition of normal 
sodium hydroxide and acetate buffera. The combination pH 
I . 
,\glass electrode was used to monitor the pH change. The dis-
'\solution. and distribution process was continued for an addi-
tonal hour. The pH was adjusted to 7.8 with normal sodium 
fYdroxide and biphosphate bufferb and the test was continued 
tn the above manner for an additional two hours. 
J. - 0.2 M Potassium Acetate. 
- 0.2 :1-1 Potassium Biphosphate. 
i·i· 
I 









Drug concentration was monitored by remOving samples 
at one hour intervals from the chloroform phase and returned 
to the distribution apparatus after spsct~dphotometric 
measurement. The absorbance measured was expressed as mg. 
percent. 
Absorption profiles were illustrated for the following 
standard drugs: Acetylsalicylic acid, phenacetin, and pheno-
barbital. The results are reported in Table II and illustrated 
in Figures 5 to 7. 
The profile of acetylsalicylic acid (Figure 5) demon-
strated a quick dissolution rate in the acidic media of the 
simulated gastric fluid because the acetylsalicyic acid 
remained in the non-ionic state and passed into the lipoid 
phase. At the pH of 7.8, the concentration of acetylsalicylic 
acid in the lipoid phase decreased. Dibbern (2) referred to 
the _phenomenon as a type of "back resorption" occurring in 
the model indicating that the acetylsalicylic exists in the 
ionized state at this elevated pH. It should be mentioned 
that this would not occur !n ~ because drug absorption is 
a dynamic process in which it would continue into the cellular 
fluid and finally to the blood plasma·. However, the in vitro 
results did indicate that !n ~ absorption of this drug 
would take place primarily in the acidic environment of the 
gastro-entera1 tract. 
The profiles for phenacetin .(Figure 6) demonstrated 
that neither solubility nor the distribution coefficient was 
influenced by pH. This was expected as phenacetin is con- · 
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TABLE I 
SPECTROPHOTOMETRIC DATA OBTAINED FOrtTHE 
PREPARATION OF THE STANDARD c-uRVES FOR T:HE DRUGS 











Phenacetin 0.0125 0.16 
0.025 0.32 
0.05 o. 70 
0.10 1.40 





a - The standard concentration in the 5 ml. sample tested was 
obtained by dissolving 100 mg., accurately weighed, in 
100 ml. of chloroform. Appropriate volumes were used, 
representing the tabulated weights. · 
b - Acetylsalicylic acid determinations were read spectro-
photometrically at 280 mu, Phenacetin at 250 mu, and 
Phenobarbital at 240 mu, using a Hitachi - Perkin Elmer 




acid, 50 mg. 
Phenacetin 
50 mg. 
ABSORPTION PROFILE DATA OBTAINED FOR THE DRUGS 






























































TABLE II (Continued) 
























a - Represents the sampling of 5 ml. of chloroform solution at 60 minute intervals for the 
specific compound under test. 
• 
b - pH of 1.2 representing the pH of simulated gastric juice; pH of 4.0 - neutralized by 
addition of normal sodium hydroxide and buffered with 0.2 ~ potassium acetate; pH of 
7.8 - further neutralization with normal sodium hydroxide and buffered with 0,2 ~ 
potassium biphosphate. 
c - Represents the calculated weight in milligrams of the sample in 200 mls. of chlcrof9;r.'!D-
solution as determined by spectrophotometric analysis and interpolation from the sampJ:e 
under test. 
d·- Represents the total percentage of the· original weight of the sample that has parti-
tioned into the chloroform layer. The values.recorded represent reproducible results. 
e - Represents the percentage of the original weight of the sample that had partitioned in 
the specific pH range under test. No percentage was reported for the thi~d hour test. 
An accumulation percentage was recorded at the end of the fourth hour, since this value 
I'epresents the total that had partitioned at the pH of 7 • a. 
..., 
-J 
1 • 1 
0.1 0.2 0.3 . 0.4 0.5 0.6 
CONCENTRATION (milligrams per 5-ml,) 
FIGURE 2 - STANDARD ACETYLSALICYLIC ACID CURVE 
.28 
CONCENTRATION (milligrams per 5-ml.) 
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FIGURE 5 - RESORPTION PROFILE - ACETYLSALICYLIC.ACID 
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at the pH's used. This was confirmed by the fadt that 
distribution of the phenacetin continued even though the pH 
of the aqueous phase was altered from acidic to an alkaline 
media. 
The profile for phenobarbital (Figure·7), a slightly 
acidic compound, showed comparable distribution t'lhen compared 
to acetylsalicylic acid at a pH of 1.2. When the pH was 
increased to a 4, an increase in resorption was still noted, 
indicating the phenobarbital was mainly in. the non-ionized 
state. Hot'lever, when the pH was increased to 7. 8, the resorp-
tion rate became weakly positive which would indicate the 
phenobarbital reverted to the partially ionized state. 
Based upon the physical and chemical characteristics 
of the three drugs tested, the profiles for each of them 
could be forecast based upon their ionizing properties. At 
the same time, the profiles could be used to forecast distri-
bution characteristics of other drugs under test based upon 
these principles. These preliminary results confirmed the 
method and results of the Desaga Resomat. Consequently, it 
appeared feasible to apply this ~ vitro model for compara-
tive measurement of gastro-intestinal .absorption of selected 
drugs. 
Dissolution Rate Studies 
It was apparent from the pharmaceutical literature that 
the term disintegration was formerly the key word in the evalua-
tion of formulations for solid dosage .forms (52). The disinte-
gration of a tablet and the in ~ availability of the drug 
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were regarded as synonymous. The introduction of sustained 
release preparations precipitated the'neod to determine more 
realistic release patterns of activE:!' ingredients from dosage 
forms. 
It was shown that disintegration tests provided no real 
index of availability of slightly water-soluble drugs within 
the body. At the same time, it.was recognized that any 
relationship between disintegration time and biological avail-
ability was not a valid means of evaluation. However, when 
the biological availability was based upon dissolution rate, 
the significant relationship is now between dissolution and 
availability. 
The importance of dissolution tests was best demon-
strated by their inclusion in the NF XIII and the USP XVIII. 
Therefore, it was decided to determine the dissolution 
rate of the drugs selected, in addition to the resorption 
studies, comparing these dissolution rates with tho.se deter-
mined by a conventional method. This would illustrate further 
the versatility of this instrument. 
In conventional dissolution studies, the extent of 
dissolution in an aqueous.system is limited by the saturation 
concentration. This could be compared to the results obtained 
from a two phase system where dissolution would proceed 
dynamically with the solute passing from the aqueous phase 
into a lipoid phase. 
Dissolution Rate - Beaker Method 
Many models for testing dissolution rates have been 
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developed, however, theh~~:YE~r method of Levy and Hayes (20) 
was chosen for this stt1dy ·b~cause of its simplicity and 
acceptance as a signifh:':arit advance in dissolu'!rion .r.ate meth-
odology. This method has been shown to compare favorably with 
in ~ biological availability. The assembly consisted of a 
400-ml. Pyrex Griffin beaker which contained 250 ml. of simu-
lated gastric, pH 1.2,· fluid which was agitated by a two blade, 
s-cm. diameter metal stirrer attached to an electronically 
controlled stirring motora. The metal stirrer was immersed in 
the dissolution medium to a depth of 27 mm. and accurately 
centered by means of a guide. The stirrer was rotated at a 
rate of 60 r.p.m. and the testtablet was placed in the solu-
tion by dropping it along the side of the beaker. The stirring 
speed was sufficient to obtain a homogeneous solution for 
sampling purposes, but sufficiently slow, so that the frag-
ments from the disintegrated tablet remained at the bottom of 
the beaker. 
Five-ml. samples were tru,en at twenty minute intervals 
and the absorbance measured spectrophotometrically at the 
appropriate wavelengths. 
Dissolution Rate - Desaga Method 
The Desaga Resomat was prepared as previously described 
under the verification of experimental procedure, except that 
the outer vessel was filled with the simulated gastric fluid 
(pH 1. 2 l instead of chloroform. The tablet dosage form was 
a - Available from Eastern Industries, Hamden, Conn. 
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placed into the sample basket a'nd immersed into the simulated 
gastric fluid. Rubber tubinr.,r: was used to connect the piston 
pump, to the glass apparatus. The system was sealed and the 
power control switches were turned on, regulating the piston 
pump and magnetic stirrers. The speed of the stirrers was 
adjusted to approximately 60 r.p.m. 
The tablet dosage forms selected were nine commonly 
used diuretics consisting of: Acetazolamidea, Chlorthalidoneb, 
Chlorthiazidec, Cyclothiazided, Ethacrynic acide, Furosemide£, 
Polythi.azideg, Spironolactoneh, and Trichlormethiazide1 • 
Samples were removed in the same manner described for 
the determination of the resorption profiles for the verifica-
tion of the experimental procedure. The samples were removed 
at twenty minute intervals over a period of two hours and the 
a - Available as Diamox 250 mg. from Lederle Laboratories, 
Pearl Ri.ver, N. Y. 
b - Available as Hygroton 100 mg. from Geigy Pharmaceuticals, 
Ardsley, N •. Y. 
c - Available as Diuril 500 mg. from Merck, Sharp and Dohme, 
• West Point, Pa. 
d - Available as Anhvdron 2 mg. from Eli Lilly and Co., 
Zndianapolis, Ind. 
e - Available as Edecrin 50 mg. from Merck, Sharp and Dohme, 
West Point, Pa. 
f -Available as Lasix 40 mg. from Hoechst Pharmaceutical Co., 
Somerville, N. J. 
g - Available as Renese 4 mg. from Pfizer Laboratories Division, 
New York, N. Y. 
- Available as Aldactone 25 mg. from G. D. Searle and Co., 
Chicago, J:ll. 
- Available as Metahydrin 4 mg. from Lakeside Laboratories, 
Inc .• , Milwaukee, Wis. 
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absorbance was measured specfrophotometrically. Each sample 
was returned through the otif.i.~~t - inlet faucet by imparting 
a vacuum to the system. 
Standard Curves 
Standard curves were prepared for the diuretics in the 
concentrations as indicated in Table III and illustrated in 
Figures 8 to 16. All dilutions were pr.epared using simulated 
gastric fluid pH 1.2. These standard curves were used to 
relate drug concentration to absorbance. 
The results of the two methods were reported in Table IV 
and Figures 17 to 25. The dissolution characteristics 'i'Tere 
represented graphically as percent concentration dissolved 
over a two hour period. In all cases, the reference points 
for the beaker method were represented by the small. circles. 
The reference points for the Desaga method were represented 
by the triangular configurations. 
Resorption Profiles 
The resorption profiles were determined for the same 
dosage forms as evaluated under the dissolution studies. 
Because the solubility characteristics of each drug varied 
in chloroform, in some instances it.was necessary to use mix-
tures of chloroform and ethyl acetate, or chloroform and 
tetrahydrofuran, as the lipoid solvent. The lipoid phase used 
for each drug was reported in Table v. 
Standard curves 
Standard curves were prepared in concentrations of active 
SPECTROPHOTOHETR!':': j,)~'a·~\ FOR THE PREPARATION 
OF THE STAND.II.RD Ctiit\'BS; FOR THE DRUGS EMPLOYED 
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TABLE Il1: (!Continued) 
============·~=····====~=========== --~cmcentrationb Drug Samplea Absorbancec 
(m.g. per 5-ml.) 
Ethacrynic Acid 0.005 . 0.09 
0.010 0.17 
0.025 0.40 
0.050 . 0.80 








Spironolactone 0.010 0.10 
0.025 0.26 
0.050 0.52 
. 0.100 1.00 





'l'ABI.E III (Continued) 
a - Samples used were the pure drug furnished by each of the 
respective pharmaceutical manufacturers. 
b - 'l'he standard concentration in the 5 ml. sample tested was 
obtained by dissolving 50 mg. in 100 ml. of gastric fluid. 
Appropriate aliquots, volumetrically measured, were taken 
representing the tabulated l<reight. 
c - Acetazolamide determinations were read at 269 mu, 
Chlorothiazide at 292 mu, Chlorthalidone at 275 mu, 
Cyclothiazide at 271 mu, Ethacrynic Acid at 271 mu, 
Furosemide at 274 mu, Polythiazide at 270 mu, 
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and lveighta Minutes 
• il.cetazolaniide 














DATA OBTAINED FOR THE TABLET DOSAGE 
FORMS El4PLOYED IN THE DISSOLUTION STUDIES 
Interpolated 
Weight for Total Interpolated 
















































' 100 mg. 
Cyc1othiazide. 
2 mg. 
TABLE IV (Continued) 
Interpolated 
Weight for Total 







































































































































































TABLE IV (Continued) 
Interpolated 






























































· Dosage For!f 
and Weight 
Trichlor-









----------:r.A13LE IV (Continued) 
Interpolated 




































a - All samples tested were tablet dosage forms. The weight indicated represent the labeled aJli:OU..':lt 
of·active ingredient in each of the tablet dosage forms specified by each of the pharm!ic~ut:,ica:t 
manufacturers. 
b - Represents the sampling of 5 ml. of simulated gastric juice at 20 minute intervals for the 
specific compound under test. 
c - Represents the calculated weight in milligrams of the sample in 250 mls. of simulated gastric 
juice as determined by spectrophotometric analysis and interpolation from the sample under test. 
d - Represents the calculated weight in milligrams of the sample in 300 mls. of simulated gastric 
juice as determined by spectrophotometric analysis and interpolation from the sample under test. 
Ul 
Ul 
TABLE ZV (Continued) 
e- Represents the percentage of the original ~reight of the sample that has.dissolved in the 
simulated gastric juice. 
f - Represents the percentage of the original weight of the sample that has dissolved in the 
simulated gastric juice. 
Ul 
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FIGURE 17 - DISSOLUTION CURVES OF ACETAZOLAMIDE 
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FIGURE l9 - DISSOLUTION CURVES OF CHLORTHALIDONE 
60 































_.. is-'J I . I ..... 







- 20 40 60 80 100 120 140 160 
TIME (Minutes) 














1/ V' I - I I I ; i 
20 40 60 80 100 120 140 160 
TIME (Minutes) 
FIGURE 21 - DISSOLUTION CURVES OF ETHACRYNIC ACID 
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FIGURE 22 - DISSOLUTION. CURVES OF FUROSEMIDE 
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FIGURE 24 - DISSOLUTION CURVES OF SPIRONOLACTONE 
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SOLVENT SYSTEMS USED AS THE LIPOID PHASE 




















b - The proportions indicate the parts by volume of each solvent used in the lipoid phase. 
These systems used were selected on the basis of their solvent characteristics on the 
specific active ingredient. lihere no co-solvent is indicated, the active ingredient 




ingredient as indicated in Table VI. wi.ltrre a solvent system 
other than chloroform, such as chloroform - ethyl acetate or 
chloroform - tetrahydrofuran was used as tlva lipoid phase in 
the determination of the resorption profiles, then these 
solvent mixtures were used in the preparation of the dilutions 
required for the standard curves. Spectrophotometric deter-
miniations were performed at the wavelepgth specified in 
Table VI. 
Resorption Profile Procedure 
In the design set up of the standard taper glass 
apparatus, the outlet-inlet ·faucets were closed, and the 
pressure equalizing "faucet"· was opened. A magnetic stirrer 
of_ 40 mm. length was inserted into the outer glass cylinder. 
T\~o-hundred ml. of lipoid solvent was then introduced into 
this cylinder. The inner glass cylinder containing a magnetic 
stirrer of 30 mm. length was lowered into the outer vessel so 
that the lower edge of the inner vessel was immersed 2 ems. 
·into the lipoid .. solvent. Precautions were taken to prevent 
the asbestos filter from coming in contact with the lipoid 
layer. While holding the inner vessel in this position, 
100 mls. of simulated gastric fluid at a pH of 1.2, was slowly 
poured into the inner glass cylinder through the opening. The 
simulated gastric fluid flowed dropwise through the asbestos 
filter onto the lipoid surface but remained within the inner 
cylinder. .The inner glass cylinder was carefully guided onto 
a teflon coated standard taper joint and secured with a gentle 
twist. ?he air which remained between the filter and the 
aqueous phase above the lipoid solvent was reJ!lGivl!.id through 
the filter by sealing the tapered openings arid by applying 
68 
a gentle vacuum to the system (J). After equ.iiizing the 
~essure within the closed apparatus, the space just below 
the filter now consisted of a two phase system consisting of 
equal parts simulated gastric fluid· and lipoid solvent. 
The assembled glass apparatus was now placed upon the 
mechanical.rnodule. The tablet dosage form representing the 
diuretic under test was placed into the tablet basket which 
was immersed 1 em. into the aqueous phase when the basket 
was placed into its appropriate setting. The glass module 
then was joined to the pump located in the module using rubber 
tubing between the appropriate connections. The system was 
sealed. So that the pH change in the aqueous phase could be 
monitored, one of the glass stoppers was replaced by the 
combination glass electrode. 
The switch located on the mechanical module was turned 
to the position marked "piston pump." With the pressure 
equalizing "faucet" open, the piston pu·mp and the magnetic 
stirrer were turned on by depressing the power switches. The 
revolutions per minute of the magnetic stirrer were adjusted 
so that a vortex of about 15 mm. in diameter was formed at the 
two phase boundary between the water and lipoid solvent. 
The control knob was then turned to "single removal," 
thus removing a sample of the lipoid solvent containing the 
resorbed diuretic. This was accomplished by closing the pres-
sure equalizing "faucet" and turning the removal pump control 
69 
knob in a counter-clockwise direction. Sitlliples were taken at 
sixty minute intervals' and measured specitrophotometrically. 
The sample was then returned to the syst~m through the outlet-
inlet "faucet" by rotating the "removal pump" control knob in 
a clock-wise direction thus imparting a vacuum to the system 
which removed the sample from the cuvette. This dissolution 
and resorption process was continued by turning the control 
knob back to the position marked "piston pump" and by opening 
the pressure equalizing "faucet." 
Standard curves that would relate absorbance to drug 
concentration were prepared in concentrations as indicated in 
Table VI and illustrated in Figures 26 to 34. After one hour 
during which a sample had been removed, tested, and returned 
to the apparatus, the simulated gastric fluid at a pH of 1.2 
was neutralized by the addition of normal sodium hydroxide. 
Then acetate buffera was added to bring the pH to 4.0. The 
combination pH glass electrode was used to monitor this pH 
change. The dissolution and resorption process \,ras continued 
for an additional hour. Sampling and testing was carried out 
as above. The pH was adjusted to 7.6 with normal sodium 
hydroxide and biphosphate bufferb. The test was continued 
in the above manner for an additional two hours and the sam-
pling was repeated. 
Drug concentration was determined spectrophotometrically 
a - o. 2 M. Potassium Acetate. 




SPECTROPHOTO~illTRIC DATA OBTAIN~D 
FOR THE PREPARATION Of THE STANDARD 
CURVES FOR THE DRUGS EMPLOYED IN THE 
DETERMINATION OF THE RESORPTION PROFILES 
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TABLE VI (Continued) 
Drug Samp1ea Concentrationb Absorbancec 























TABLE VI (Continued) 









a - Samples used were the pure drug furnished by each of the 
respective pharmaceutical manufacturers. 
b - The standard concentration in the 5 ml. sample tested was 
obtain~d by dissolving 50 mg., accurately weighed, in 
100 ml. of chloroform.· Appropriate volumes were used. 
representing the tabulated weights. 
c- Acetazolamide absorbancy determinations. were read spcctro-
photometrically at 269 mu, Chlorothiazide at 292 mu, 
Chlorthalidone at 275 mu, cyclothiazide at 271 mu, 
_Ethacrynic Acid at 271 mu, Furosemide at 274 mu, 
Polythiazide at 270 mu, Spironolactone at 245 mu, and 
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FIGURE 30 - STANDARD ETHACRYNIC ACID CURVE 
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0.14 0.16 ' 
by removing samples from the lipoid phase'ri:'t one hour 
intervals. The samples were returned to the distribution 
apparatus after each measttrement. 
82 
The results were reported in Table VII and the resorp-









RESORPTION PROFILE DATA OBTAINED FROM THE DOSAGE FORMS 
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TABLE VJ:J: (Continued) 

























































TABLE VII (Continued) 
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a - All samples tested were tablet dosage forms. 'l'he weiqht indicated represents the labeled 
amount of active inqredient in each of the tablet dosaqe forms as specified by each of 
the pharmaceutical manufacturers. 
b - Represents the sampling of 5 ml. of lipoid solvent at 60 minute intervals for the specified 
dosage form under test. 
c - pH of 1.2 represents the pH of simulated gastric juice; pH of 4.0 - neutralized by addition 
of normal sodium hydroxide and buffered with 0.2 M potassium acetate; pH of 7.8, further 
neutralization with normal sodium hydroxide and buffered with 0.2 M potassium biphosphate. 
d - Represents the calculated weight in milligrams of the active ingredient in 200 mls. of 
lipoid solvent as determined by interpolation of spectrophotometric analysis for each 
sample under test. 
Cl) 
~ 
TABLE VII (Continued) 
e - Represents the total percentage of the original weight of the sample that had partitioned · 
into the lipoid phase at the various time intervals. 
f - Represents the percentage of the original weight of the sample that had partitioned in the 
specific pH range under test. No percentage increase was reported for the third hour test. 
The percentage increase was recorded at the end of the fourth hour, since this value 
represented the total that had partitioned at the pH of 7.8. 
-. ---·------------------------------------
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FIGURE 36 - RESORPTION PROFILE - CHLOROTHIAZIDE 





















FIGURE 37 - RESORPTION PROFILE - CHLORTHALIDONE 
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FIGURE 38 - RESORPTION PROFILE - CYCLOTHIAZIDE 
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FIGURE 40 - RESORPTION PROFILE - FUROSEMIDE 
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FIGURE 42 - RESORPTION PROFILE - SPIRONOLACTONE 
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FIGURE 43 - RESORPTION PROFILE - TRICHLORMETHIAZIDE 
DISCUSSION 
The results obtained from experiments conducted with 
the Desaga Resomat provided useful information for application 
to other projects involving resorption or absorption of 
organic drugs. 
A preliminary discussion of the absorption profiles 
used to verify operational principles has already been included 
in the experimental procedure. It was included at that time to 
support the experimental results that would establish the 
instrument as a valuable tool in predicting absorption charac-
teristic~ of organic compounds other than those under test. 
Howeve.t·, a further discussion of these results was deemed 
feasible to fully evaluate the !u vitro model and its applica-
tion. 
In a distribution system, a situation exists where the 
active ingredient was partially dissolved in its aqueous dis-
solution medium. Only this dissolved portion of the drug would 
be available for distribution or partitioning into the adjoin-
ing lipoid phase. Dibbern (1, 2) used this assumption as his 
first criterion or principle for the development of his test 
apparatus. For the dissolved portion of the drug to partition, 
it was also necessary for the aqueous phase of the binary sys-
tem to be in an active state of "physical involvement" with 
the lipoid phase. Th~• procedure t:as designed so that the 
aqueous phase compared favorably with the !a~ conditions 
! 
: ;~.:· f : 
~~:. l r 





by using simulated gastric juice. Also, the non-polar solvent 
as the adjoining phase would simulate the lipoid barrier or 
membrane. The asbestos filter would prevent any fragments of 
the drug or its dosage form from entering this lipoid phase. 
At the same time, the alternating pressure on the system pro-
duces a movement comparable to peristalsis and would bring the 
dissolved drug to the lipoid boundary, .setting up conditions 
for partitioning. The extent of the drug partitioning could 
be monitored by a suitable analytical procedure. 
Generally, most organic compounds are absorbed or par-
titioned by passive diffusion (.3). For passive diffusion to 
take place, certain conditions must prevail in the system. 
There mus~ be a drug concentration gradient on each side of 
the membrane or barrier. As the concentration begins to 
equalize itself in each of the phases, diffusion will be 
reduced or will cease. Also, the diffusion rate will be based 
on the partition coefficient characteristics of the drug • 
. Probably, the most important factor controlling the diffusion 
is referred to as the "pH-partition" theory ( 3) • This ·theory 
defines the role that pH exerts on the diffusion of the com-
pound as it passes along the natural absorption sites from 
the stomach to the large intestine. Since drugs can diffuse 
into the lipoid phase only as the undissociated molecule, it 
would actually be the pH of the environment that would control 
dissociation and hence the ability topartition. The pH 
characteristics promoting the ionization of the compound would 
inhibit diffusion, since the ionized state of a compound lacks 
100 
lipoid solubility properties. 
Weakly acidic drugs exist primarily as the undis-
sociated molecule at the pH of the stomach. Hence, their 
absorption by partitioning would be favored from this acidic 
environment. Conversely, weakly basic drugs would exist in 
the same site as the dissociated or cationic state and, there-
fore, would not be absorbed. The difference in absorption of 
two compounds of the same acidic character, would depend on 
their pKa• Weakly basic drugs, which would be present in the 
dissociated form in the gastric contents, would revert to the 
undissociated state at the slightly alkaline pH of the small 
intestine. This would favor their absorption across the 
'•;· 
barrier at this site. 
Neutral compounds would not be affected by the pH of 
the environment in either the stomach or the small intestine. 
Hence, their absorption would proceed favorably along the 
entire absorption area. The only controlling factors would 
be the solubility or partitioning characteristics of the par-
ticular drug, as well as the concentration gradient of the 
drug on each side of the partitioning membrane. 
These principles or theories were supported by the 
absorption profiles for the drugs initially tested with the 
Desaga Resomat. Figure 5 illustrated the absorption profile 
for acetylsalicylic acid. Acetylsalicylic acid is a weak acid 
with a pKa o£ 3.4. The profile indicated that partitioning . 
had proceeded readily, even when the pH of the medium had been 
increased to 4.0. However, as the pH was increased to 7.8, 
the acetylsal.icylic acid should.have almost completely ionized 
101 
to the dissociated state •. Hence, H: would no longer partition 
into the lipoid solvent. necause of the extensive resorption 
of the acetylsalicylic acid in the acidic pH, and also the 
fact that the compound had ionized in the aikaline medium, 
the concentration gradient favored the diffusion of the ionized 
acetylsalicylic acid back into the aqueous phase. This phe-
nomenon is referred to as reverse diffusion or more commonly 
as "back resorption. " This condition would not occur ,!!l ~. 
since a dynamic state would exist which would dissipate the 
partitioned acetylsalicylic acid as quickly as it diffused. 
In summary. acetylsalicylic .acid would be readily absorbed 
from the stomach but not from the small intestine. This fact 
has been quantitatively illustrated in Table J:J:. 
Phenacetin is considered to be a neutral compound with 
no pH dependent ionizing characteristics. Therefore, parti-
tioning mechanisms would be independent of any changes in pH. 
This_fact was illustrated in Figure 6, the resorption profile 
for this compound. Because phenacetin is only slightly solu-
ble in water, this property was the controlling factor for the 
low resorption quota. Specifically, the profile did indicate 
that resorption or partitioning was independent of the pH 
environment. 
Phenobarbital is considered to be a weak acid, having 
a pKa of 7.4. The drug would be expected to exist primarily 
in its undisso.ciated form at the pH of the stomach with an 
anticipated high resorption value. Hot'lE!ver, phenobarbital is 
a relatively insoluble compound at the pH of the simulated 
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gastric contents. Hence, it was the lO'I-! soli.lbility properties 
of the phenobarbital that were responsible for the low resorp-
tion properties. This was illustrated in the resorption pro-
file in Figure 7. When the pH of the medium is increased, the 
solution of phenobarbital in water also increases. This was 
noted in the profile when the pH was increased to 4.~ where a 
higher resorption value was illustrated. A further increase 
in pH to 7.8, promoted the ionization of the compound. This 
condition became the limiting factor in the resorption of the 
phenobarbital. This was illustrated by the weak resorption 
in the alkaline pH. 
Dissolution Studies 
Dissolution implies the solubilizing of a compound in 
a specific solvent. One of the factors controlling the dis-
solution rate of a compound is the extent to which the con-
centration builds up in the dissolution medium. This increase 
in concentration will have a retarding effect on the rate of 
dissolution, up to the point of saturation, where the dissolu-
tior• will cease. !'lith sparingly soluble drugs, the effect of 
increased concentration becomes very apparent. Therefore, 
many of the established ill. vitro dissolution rate methods were 
unable to accurately evaluate the dissolution rate of these 
sparingly soluble drugs. Consequently, dissolution studies 
were included in this project primarily, to illustrate and 
evaluate the solubility characteristics of the diuretics. By 
using the Desaga Resomat for these determinations, the versa-




the Resomat dissolution rates, they were cOmpared to the 
Beaker Method (20) I a procedure that n<is pt·ov~n satisfactory 
for expressing dissolution rate characteristics of compounds 
in oral dosage forms. Comparative dissolution characteristics 
of the diuretics were indicated in Table IV and their dissolu-
-
tion rates illustrated graphically in Figures 17 to 25. 
It was noted that while the dissolution characteristics 
were not the same for each period of testing by either method, 
the over-all extent of dissolution for the majority of the 
diuretics compared favorably at the end of the test period. 
Wfiere differences were noted, several factors·should be con-
sidered. It was possible that the dissolution rate of the 
active ingredient was affected by the disintegration rate of 
the tablet. Variations in disintegration rates have been 
noted to occur with tablets having the same lot numbers. 
A possible explanation for the slightly slower rate of 
dissolution with the Desaga Resomat was the fact that after 
the active ingredient dissolved, it had to diffuse through the 
asbestos pad into the medium that was actually tested. Also, 
the rate of agitation could account for differences in the 
dissolution rate. With the Beaker Method, agitation was con-
trolled in such a manner that the tablet fragments were 
restricted to the bottom of the beaker. However 1 in the Resomat, 
the two magnetic stirrers and the alternating pressure imposed 
on the system maintained the fragments in active dispersion. 
Finally, the variations in test volumes for each of the methods 
' 










Therefore, it was established that the Desaga Resomat 
could be used as an instrument for the· determination of dis-
solution rates of table.t. · 
Resorotion Profiles 
A resorption profile is a graphical illustration of 
the partitioning of a drug from an aqueous phase into a lipoid 
medium at specific pH values. The Desa.ga Resomat is designed 
in such a manner that the aqueous medium will be in equilibrium 
,,.ith a non-polar solvent. The aqueous medium with its varying 
pH '"ould simulate the physiological variation from the gastric 
contents to that of the small intestine. The non-polar sol-
vent would approximate the properties of the lipoid membrane 
'through which the drug partitions in the absorption process. 
Profiles were obtained by plotting percent resorption 
as a function of time. Changes in pH characteristics were 




Acetazolamide is described as a weak acid with a pKa of 
7.2. It possesses low water solubility properties as illus-
trated in Figure 17. It would be expected, based upon the 
"pH-partition" theory, that the distribution coefficient would 
be higher in the more acidic medium. However, the profile 
indicated a relatively low distribution at this pH. This could 
be explained on the basis of the low solubility characteristics 








that the distribution would decrease. E'>lidently, there was 
sufficient drug in the nonionized state to partition,_ thus-
maintainin9- an unaltered distributi6r!' rate. Therefore, the 
profile would indicate absorption of this drug taking place 
over the entire pH range. However, distribution is limited 
because of its solubility characteristics. Reported data (53) 
indicate that the compound was stable in vivo, and that the 
compound was absorbed along the entire gastro-intestinal 
tract and excreted unchanged. 
Ch1orothiazide Profile 
Chlorothiazide is described as a weak acid with a pKa 
of 6. 7 (54). It exhibits low water solubility as illustrated 
in Figure 18. The profile, Figure 36, indicated a low drug 
distribution into the lipoid phase. The property of low 
aqueous solubility, would be a contributing factor. However, 
as the pH increases, chlorothiazide's water solubility also 
increases (55). This accounted for th~ increase in distribu-
tion occurr.ing at a pH of 4.0. The increased solubility 
favored distribution even though dissociation may have occurred. 
However, as the pH increased to 7.8, ionizing characteristics 
of the compound would become the limiting factor. Thus 
accounting for reduced resorption quota. Therefore, from the 
analysis o.f the solubility characteristics and the profile for 
chlorothiazide, it may be postulated that chlorothiazide would 
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Chlorthalidone Profile 
Chlorthalidone is a weak acid with a pKa of 7. 0 (55)~ 
Fiqur~ 19, indica ted that . the compound shot1ed some solubility 
in the aqueous medium. The solubility increased as the pH 
increased (55). Figure 37, the resorption profile for 
chlorthalidone, indicated that the partitioning properties 
of the compound were independent of any changes in pH. The 
uniformity of partitioning over the entire pH range was due 
to the increased solubility characteristics compensating for 
any inhibiting effect due to ionization. Thus this profile 
would forecast that the in vivo absorption sites would be over 
the entire gastro-intestinal course. 
eyclothiazide Profile 
Cyclothiazide is a weruc acid .with a reported pKa approxi-
mating 7 (55). Its solubility characteristics, .Figur.e 20, at 
a pH of 1.2 were considerably higher than for other compounds 
.. 
tested. This dosage form exhibited particularly prolonged 
disintegration properties. The absorption profile, Figure 38, 
indicated a relatively low distribution at a pH of 1.2. The 
"pH-partition" theory would forecast good distribution charac-
teristics. The low distribution at this pH could be due to a 
decreased availability of the cyclothiazide due to the poor 
disintegration properties of the tablet. However, as the pH 
was increased to 4.0, a marked increase in distribution became 
apparent from the profile. The increased partitioning could 
be explained on the b.>sis of a high solubility of cyclothiazide 














partitioning properties. would also account ~rthei continued 
distribution at a pH of 7.8. 'l'he profile wtnfld; therefore, 
indicate a slower onset of absorption but that the absorption 
would continue over the entire gastro-intestinal absorption 
sites. 
Ethacrynic Acid Profile 
Ethacrynic acid is a weak acid and has a reported pK . a 
of 3.5 (56). It exhibited poor water solubility character-
istics at a pH of 1.2 as illustrated in Figure 21. Based upon 
its pi<a, a high distribution could be anticipated. 'l'his pos-
tulation can be made because the compound would exist as the 
undissociated molecule at the pH 1.2 which would favor marked 
partitioning into the lipoid solvent. However, the low dis-
solution properties of the compound evidently restricted the 
distribution at this pH. 'l'he dosage form also exhibited pro-
longed disintegration characteristics in the test medium. 
This would also account for the limited availability of the 
ethacrynic acid for distribution. Due to the pKa value of the 
compound, the ethacrynic acid would become highly ionized with 
an increase in pH. The concentration gradient would favor a 
"reverse resorption" of the ionized ethacrynic acid back into 
the aqueous medium. 'l'he profile indicated that the compound 
would be absorbed only from the stomach. 
Furosemide Profile 
Dibbern (1) has described Furosemide as a weak acid. 










solvents. From the dissolution stt1dy. Figure 22, Furosemide 
exhibited a low water solubilit~t•""' This would increase with 
an increase in pH (55). From t:liEi absorption profile, the low· 
resorption rate was attributed to the low water solubility 
characteristics at the lower pH. However, as the pH increased, 
even though a reduced partitioning might be anticipated due to 
ionization, the reverse was noted in th.e profile, Figure 40. 
The increase in the resorption quota at the elevated pH values 
was probably due to the enhanced solubilizing affect of the 
medium. From the profile data, particularly in the pH range 
of 7.8, it could be assumed that almost ali of the nonionized 
Furosemide was partitioned. The data presented would indicate 
that Furosemide would partition over the entire gastro-
intestinal tract with the absorption increasing as the pH of 
the absorption sites increased. 
Polythiazide Profile 
Polythiazide is a weak acid. The data, as shown in 
Figure 23, showed that the compound was soluble in simulated 
gastric fluid. The resorption profile of Polythiazide, 
Figure 41, resellibled that of a neutral compound. - However, 
Poiythiazide is readily soluble in an alkaline medium (55). 
The high degree of solubility appeared to compensate for any 
effect that ionization may have had upon resorption. A good 
resorption quota was shown in the strongly acidic pH. As the 
' 
pH was rais_ed, a slight decrease in the resorption quota was 










that absorption would proceed over t:lie entire gastro-intestinal 
tract. Reported data (57) supported this profile~ Poly-
thiazide was described as.a potent diuretic with an onset of 
action occurring within two hours, and with a prolonged action• 
Spironolactone Profile 
Spironolactone is described as an ester. The data, as 
shown in Figure 24, indicated that the compound has low water 
solubility characteristics. From the profile data, Figure 42, 
the compound adhered to the "pH-partition"· theory with a more 
pronounced distribution occurring in the more acidic medium. 
As the Spironolactone partitioned, however, more would be~ome 
available through dissolution. Thus, distribution continued 
at both increased pH values. The marked reduction in this 
process at the end of the third hour of testing was possibly 
due to two factors. It was possible that the lipoid solvent 
had approached saturation with respect to Spironolactone in 
solution. Also, the Spironolactone tablet formulation 
·appeared to release an "oily" material 'Which tended to clog 
the sintered filter. This had an impeding effect on the 
passage of the aqueous medium through the filter thus inhibit-
ing contact with the lipoid solvent. The profile would pre-
dict that Spironolactone would be absorbed in vivo over the 
entire pH range of the gastro-intestinal tract but would be 
time limited at the pH of the small intestine. 
Trichlormethiazide Profile 
·Trichlormethiazide is a weak acid and exhibited good 









solubility in simulated gastric fluid. The solubility was 
illustrated .in Figure 25. Trichlormethiazide wotild be 
-
expected to show a high resorption at a pH of ·1.2 because of 
minimal ionization and the enhanced solubility. The resorp-
tion profile, Figure 431 illustrated this phenomenon. When 
the pH was increased to 4.0, the resorption rate decreased 
slightly. This indicated that Trichlormethiazide had under-
gone ionization. However, the solubility of Trichlormethiazide 
increased as the pH was increased into an alkaline range (57). 
Therefore, partitioning would still occur as a result of this 
increased solubility. The effect of ionization on the drug 
was illustrated in the alkaline pH as only a slight increase. 
in resorption was noted in this range. Increased ionization 
of the compound would be the contributing factor. In summary, 
it appeared that Trichlormethiazide would be absorbed from the 
entire gastro-intestinal tract, with the highest resorption 
quota occurring in the stomach. This profile compared with 
reported data (57) that Trichlormethiazide is a potent diuretic. 
Onset of action occurs within two hours with moderate diuresis 





































l. The literature surveying the history of dissolution 
rate methodology and its.influence on the bio-availability of 
medication from the dosage form has been reviewed. 
2. Experiments to verify the Desaga Resomat as a use-
ful instrument in predicting gastro-intestinal absorption 
have been conducted. 
3. Resorption profiles for acetylsalicylic acid, 
phenacetin, and phenobarbital were used in the verification 
of the Desaga Resomat were graphically illustrated. 
4. Standard curves were prepared relating concentra-
tion of drug in simulated gastric fluid to absorbance by 
spectrophotometric analysis. These curves were used to deter-
mine the amount of drug dissolved in the dissolution medium. 
5. Experimental dissolution rate studies were carried 
out and graphically illustrated, by two methods; the Desaga 
Resomat and a previously. reported procedure known as the Beru,er 
Method. 
6. Standard curves were prepared which related con-
centration of drug in the various lipoid solvents used in this 
study. 
7. Nine diuretics, of current interest, were tested by 
the Desaga Resomat procedure .and their resorption profiles 




















The results obtained from experiments with the Desaga 
Resomat provided useful information ab,out dosage form charac-
teristics and the availability of the active ingredient from 
the formulation. 
The Desaga Resomat was developed primarily for absorp-
tion model experiments utilizing a binary system. The instru-
ment, however, is not limited to just this application. Dis-
regarding distribution into .an immiscible solvent, the Desaga 
Resomat could be used for the determination of the simple rate 
of release of the active ingredient from tablet dosage form. 
The results of this study compared favorably with data supplied. 
by an accepted method used in dissolution rate methodology. 
··~ . ~. •,.(! 
The. advantages of the instrument used for this purpose over 
other methods arise from the convenience and ease in varying 
the conditions which alter dissolution rate characteristics~ 
The Desaga Resomat permitted the determination .of 
resorption profiles which illustrated the result of aqueous 
solubility and the distribution of a drug into a lipoid phase. 
The resorption profiles of the drugs used in establish-
ing the efficacy of the Desaga Resomat illustrated that drug 
absorption is primarily dependent upon the "pH-partition" 
theory. These profiles supported this theory that a membrane 
is more permeable to the nonioni?ed form of a drug due to its 
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the membrane becomes a function of the pH of the internal 
environment and the pKa value of the particular drug. Con-
sequently, a weak acid v1ould be absorbed more extensively at 
a lower pH because of its minimal dissociation. Conversely, • 
a weak base would have enhanced absorption at the pH values 
common to the small intestine. 
The resorption profiles tgere det.ermined for nine 
diuretic drugs. Their ~ vivo absorption characteristics 
could be predicted based upon these profiles. The inter-
dependency of aqueous solubility, distribution coefficient, 
and changing pH was shown to influence the resorption of these 
drugs in vitro. These factors also control the absorption 
process in the gastro-intestinal tract (l-5). 
The ideal situation, based upon the "pH-partition" 
theory, was shown with those drugs having a low pKa. Dis-
sociation of.these drugs was minimal in the strongly acidic 
' ·.~medium, favoring absorption from this site. However, the pro-
files illustrated the effect of other factors on absorption. 
Initial availability of active ingredient was controlled by the 
disintegration rate of the dosage form, solubility character-
istics of active ingredient in aqueous medium and the degree 
of ionization of fhe drug at the specific pH value. The pro-
files also ilJ.ustrated the influence .of concentration gradients 
existing in the binary system. Conditions favoring approach-
ing saturation of active ingredient in the lipoid phase would 
be a rate limiting factor in in vitro drug-absorption. 
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could be applied to prediction of in vi<~m. availability 
·characteristics of tablet dosage forms. There is still some 
doubt associated with correlating J7esults of .!!! vitro tests 
with actual 1:!! vivo conditions (58). Hot"ever, it is agreed 
that if a dosage form does not perform satisfactorily in an 
in vitro test, it would be doubtful that release of active 
ingredient from the dosage form would occur 1:!! vivo. It is 
also agreed that a well-formulated tablet that passes the 
rigorous j,n vitro testing for drug availability will have a 
much greater chance of clinical success. Thus, the Desaga 
Resomat presents an ins~ument with the potential of provid-
ing information which previously was only available from 
in vivo studies. --
: I 
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